A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis

BACKGROUND: Cirrhosis and acute-on-chronic liver failure (ACLF) are associated with systemic inflammation, and caspase-mediated hepatocyte cell death. Emricasan is a novel, pan-caspase inhibitor. Aims of this study were to assess the pharmacokinetics, pharmacodynamics, safety and clinical outcomes o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Exp Hepatol
Autors principals: Mehta, Gautam, Rousell, Sam, Burgess, Gary, Morris, Mark, Wright, Gavin, McPherson, Stuart, Frenette, Catherine, Cave, Matthew, Hagerty, David T., Spada, Alfred, Jalan, Rajiv
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2018
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6175779/
https://ncbi.nlm.nih.gov/pubmed/30302038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jceh.2017.11.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars